Camilla Hansen joined Seed Investments in June of 2018.
Camilla brings 10 years of business development experience from early academic start-up to industry. Most recently, Camilla was responsible for scouting and building new growth platforms for Novozymes A/S. Prior to that, Camilla held a business development position at Statens Serum Institute (SSI) where she was commercializing preclinical and clinical life science products and projects, in addition to being instrumental in divesting the Vaccine Production business from SSI.
From 2009 to 2012 she worked in technology transfer at Wake Forest University Health Sciences in the US where she was involved in out licensing and commercializing early and mid-stage assets, including company creation.
Camilla has a PhD in Medicinal Chemistry and a Master of Pharmacy degree from Copenhagen University.